Literature DB >> 12199487

Measuring the success of treatment for chronic obstructive pulmonary disease--patient, physician and healthcare payer perspectives.

T Van der Molen1, W Pieters, D Bellamy, R Taylor.   

Abstract

The success of treatments for chronic obstructive pulmonary disease (COPD) is evaluated by measuring the impact on a range of health outcomes. However, outcome measures differ in their relative importance to the various stakeholder groups. Patients are most interested in the impact on quality of life and on mortality, while physicians also value information about the effect of treatments on lung function and disease progression. In contrast to patients and physicians, healthcare payers take a population perspective, and need to balance the health gains achieved and the costs of treatment. If the management of COPD is to be improved, it is important, first, to understand the outcomes of importance to each relevant stakeholder group, and then second, to refocus the measures in terms that all stakeholders can value.

Entities:  

Mesh:

Year:  2002        PMID: 12199487     DOI: 10.1016/s0954-6111(02)80030-0

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  3 in total

Review 1.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Authors:  Donald P Tashkin; Leonardo M Fabbri
Journal:  Respir Res       Date:  2010-10-29

Review 2.  Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.

Authors:  Robert A Stockley; Philip J Whitehead; Michael K Williams
Journal:  Respir Res       Date:  2006-12-29

3.  COPD: understanding patients' adherence to inhaled medications.

Authors:  António Duarte-de-Araújo; Pedro Teixeira; Venceslau Hespanhol; Jaime Correia-de-Sousa
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-09-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.